A pilot study by Okushin et al. showed that multiple daily dosing with intravenous IFN-β produced therapeutic effects similar to those achieved by 24 weeks of Peg-IFN-α2a treatment in patients with chronic hepatitis B [18]. Here, IFNB1 is linked to chronic hepatitis B virus infection.